All In Biotech

NDA 020163 · Vantive US Hlthcare

Dianeal Pd-2 W/ Dextrose 4.25% In Plastic Container

Calcium Chloride, Dextrose, Magnesium Chloride, Sodium Chloride, Sodium Lactate · Intraperitoneal

Last checked: Nov 19, 2026Latest source record: Jun 5, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1992

Dec 4, 1992

Approved uses

1

Original approval plus efficacy supplements

Registered trials

9,299

2,122 Phase 3, 968 recruiting

FAERS reports

7,211

6,395 serious, 3,287 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 16, 2026.

DIANEAL peritoneal dialysis solutions are indicated for patients in acute or chronic renal failure. For management of acute or chronic renal failure.

Mechanism: DIANEAL peritoneal dialysis solutions are a pharmacologically inactive, hypertonic peritoneal dialysis solution containing dextrose, a monosaccharide, as the primary osmotic agent. An osmotic gradient must be created between the peritoneal membrane and the dialysis solution in order for ultrafiltration to occur. The hypertonic concentration of glucose in DIANEAL solutions exert an osmotic pressure across the peritoneal membrane resulting in transcapillary ultrafiltration. Like other peritoneal dialysis solutions, DIANEAL solutions contain electrolytes to facilitate the correction of...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 4, 1992 Original approval · Type 5 - New Formulation or New Manufacturer
3 products under this application
  • DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER · CALCIUM CHLORIDE 25.7MG/100ML; DEXTROSE 4.25GM/100ML; MAGNESIUM CHLORIDE 5.08MG/100ML; SODIUM CHLORIDE 538MG/100ML; SODIUM LACTATE 448MG/100ML · SOLUTION, INTRAPERITONEAL · Prescription · TE AT
  • DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER · CALCIUM CHLORIDE 25.7MG/100ML; DEXTROSE 1.5GM/100ML; MAGNESIUM CHLORIDE 5.08MG/100ML; SODIUM CHLORIDE 538MG/100ML; SODIUM LACTATE 448MG/100ML · SOLUTION, INTRAPERITONEAL · Prescription · TE AT
  • DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER · CALCIUM CHLORIDE 25.7MG/100ML; DEXTROSE 2.5GM/100ML; MAGNESIUM CHLORIDE 5.08MG/100ML; SODIUM CHLORIDE 538MG/100ML; SODIUM LACTATE 448MG/100ML · SOLUTION, INTRAPERITONEAL · Prescription · TE AT

Clinical trials

Interventional ClinicalTrials.gov studies with "Chloride" as an intervention, any sponsor and status, largest first.

All 9,299 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death1,002
  • peritonitis516
  • myocardial infarction499
  • cardiac failure congestive419
  • sepsis363
  • infection348
  • hypotension332
  • cardio-respiratory arrest321
  • acute myocardial infarction295
  • peritoneal dialysis complication282
  • pneumonia232
  • fluid overload218

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20111
201211
201319
20141,235
20152,700
20161,004
2017543
2018274
2019289
2020214
202145
2022278
2023172
2024169
2025172
202685

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Aug 3, 2026

    DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0427-53). A business decision was made to discontinue manufacture of...

  • To Be Discontinued · updated Aug 3, 2026

    DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0426-53). A business decision was made to discontinue manufacture of...

  • To Be Discontinued · updated Aug 3, 2026

    DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0426-52). A business decision was made to discontinue manufacture of...

  • To Be Discontinued · updated Aug 3, 2026

    DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0427-52). A business decision was made to discontinue manufacture of...

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,091 on PubMed

Sponsor: Vantive US Hlthcare · Also marketed as Dianeal Pd-2 W/ Dextrose 1.5% In Plastic Container, Dianeal Pd-2 W/ Dextrose 2.5% In Plastic Container

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.